A recent phase Ib clinical trial (KEYNOTE-012) has shown that Pembrolizumab, an anti-PD-L1 monoclonal antibody, can result in an antitumor response rate as high as 22% in patients with PD-L1-positive advanced gastric cancer, thereby demonstrating the robust, durable responses of antibody therapy in patients with gastric cancer [9]. The gene discussed is CD274; the disease is gastric cancer.